The drug currently approved for chronic kidney disease (CKD) associated with type 2 diabetes, may benefit a much broader group of patients than previously recognized
Teva said the launch strengthens its biosimilars strategy and expands access to biologic medicines across Europe
Targeting deadly drug-resistant acinetobacter infections
DST-backed researchers from Pune demonstrate targeted gene-silencing approach that significantly inhibits tumor growth with minimal toxicity
Highlights potential for at-home heart attack risk assessment, offering a new approach to reducing treatment delays
The industry is expected to grow significantly over the next few years as healthcare accessibility improves and insurance penetration increases
At the center of the project is a new cosmetics line developed through collaboration between industry and medicine
The filing is backed by Phase III data from the lidERA Breast Cancer study
The companies say the drug has now demonstrated clinical benefit in three separate Phase 3 trials
The transaction includes an upfront payment of $1.55 billion, along with up to $1.1 billion in regulatory and commercial milestone payments
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
